Join Growin Stock Community!

Viking therapeutics, inc.VKTX.US Overview

US StockHealthcare
(No presentation for VKTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

VKTX AI Insights

VKTX Overall Performance

VKTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VKTX Recent Performance

-0.27%

Viking therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

VKTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

VKTX Key Information

VKTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

VKTX Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Price of VKTX

VKTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VKTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.96
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.96
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is VKTX's latest earnings report released?

    The most recent financial report for Viking therapeutics, inc. (VKTX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VKTX's short-term business performance and financial health. For the latest updates on VKTX's earnings releases, visit this page regularly.

  • How much cash does VKTX have?

    At the end of the period, Viking therapeutics, inc. (VKTX) held Total Cash and Cash Equivalents of 165.86M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is VKTX's EPS continuing to grow?

    According to the past four quarterly reports, Viking therapeutics, inc. (VKTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.39. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VKTX?

    Viking therapeutics, inc. (VKTX)'s Free Cash Flow (FCF) for the period is -85.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 173.53% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of VKTX?

    The latest valuation data shows Viking therapeutics, inc. (VKTX) has a Price-To-Earnings (PE) ratio of -9.17 and a Price/Earnings-To-Growth (PEG) ratio of -0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.